The OsteoStrand Plus Deformity Study
1 other identifier
interventional
28
1 country
1
Brief Summary
A clinical study evaluating outcomes for patients with spinal deformity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 5, 2020
CompletedFirst Submitted
Initial submission to the registry
November 5, 2020
CompletedFirst Posted
Study publicly available on registry
November 16, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2024
CompletedApril 4, 2023
March 1, 2023
4.1 years
November 5, 2020
March 30, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Assessment of fusion for the demineralized bone matrix cohort vs bone morphogenic protein cohort
Proportion of spinal levels in the demineralized bone matrix cohort vs bone morphogenic protein cohort achieving fusion.
12 Months
Secondary Outcomes (1)
Clinical outcomes
24 Months
Study Arms (2)
Demineralized Bone Matrix
ACTIVE COMPARATORProspective cohort subjects undergoing deformity correction surgery that receive Demineralized Bone Matrix (DBM).
Bone Morphogenic Protein
ACTIVE COMPARATORRetrospective cohort subjects that underwent deformity correction surgery and received Bone Morphogenic Protein (BMP).
Interventions
Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
Posterolateral Lumbar Fusion with Bone Morphogenic Protein
Eligibility Criteria
You may qualify if:
- ≥18 years of age
- Indicated for deformity correction surgery
- Require spinal fusion at four or more levels
- Are willing to return for follow-up visits
- Willing to sign the Informed Consent Forms
You may not qualify if:
- Uncontrolled diabetes
- Morbid obesity
- history of alcohol or drug abuse
- Corticosteroid use
- Fever or leukocytosis
- Systemic infection
- Active malignancy
- Elevation of white blood cell count
- Osteoporosis
- Disease of bone metabolism
- Unsuitable or insufficient bone support
- Skeletal immaturity
- Prior fusion
- Use of steroids, immune suppressants, osteoporosis medications
- Use of internal bone stimulators
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- SeaSpine, Inc.lead
Study Sites (1)
Sonoran Spine
Tempe, Arizona, 85281, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Chang, MD
Sonoran Spine
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 5, 2020
First Posted
November 16, 2020
Study Start
March 5, 2020
Primary Completion
March 31, 2024
Study Completion
June 30, 2024
Last Updated
April 4, 2023
Record last verified: 2023-03